Nimotuzumab with Induction Chemotherapy and Chemo-Radiation in Patients with Advanced Head and Neck Cancer
Read full paper at: http://www.scirp.org/journal/PaperInformation.aspx?PaperID=53685#.VM80sizQrzE Author(s) Sundaram Subramanium 1* , Venkatanarayan Balasundaram 2 , Sridharan Nithya 1 , Poojar Kiran 3 Affiliation(s) 1 Medical Oncology, V. S. Hospital, Chennai, India . 2 Radiation Oncology, V. S. Hospital, Chennai, India . 3 Clinical Pharmacology, Biocon, Bangalore, India . ABSTRACT Background: Head and neck squamous cell carcinoma (HNSCC), is a common malignancy in the Indian Population. In locally advanced disease, chemoradiation is the standard of care. Although induction chemotherapy has been much studied, no clear benefit has been identified apart from laryngeal preservation. A few randomized trials have demonstrated improved response rate, disease free survival, and overall survival, with induction chemotherapy. Nimotuzumab is a humanized monoclonal antibody targeting epidermal growth factor receptors (EGFR)....